Losses mount at Resonant, but CEO predicts big things as 5G future approaches
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA accuses Amgen of misleading advertising
The U.S. Food and Drug Administration tagged Amgen with a letter July 7 that says the Thousand Oaks biotech firm made “misleading claims” in advertisements for its drug Neulasta, by suggesting it is more effective than biosimilar competitors. Neulasta is a prescription medication used to reduce infection risk from febrile neutropenia (a low level of Read More →
Income up at Community Bank of Santa Maria
Community Bank of Santa Maria saw its net income rise more than 35% for the most recent quarter as total assets, deposits and net loans all increased. In a July 13 earnings statement, the bank reported net income of $1.44 million for the quarter ended June 30, 36.1% higher than the same quarter of the Read More →
FDA gives Amgen priority review for asthma treatment
Thousand Oaks-based Amgen received a priority review for tezepelumab, a treatment for asthma, from the U.S. Food and Drug Administration, the biotech giant announced July 7. According to Amgen, tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of clients in phase 2 and 3 trials. Read More →
Trade Desk unveils new ad platform it calls ‘biggest release ever’
Shares of The Trade Desk rose by as much as 5% on July 7, as the Ventura-based advertising technology company unveiled its new trading platform, Solimar. The Trade Desk closed at $76.56 on July 6 and traded as high as $81.59 on July 7 before closing at $77.65, up 1.5% from the previous closing date. Read More →
Procore expands into Middle East and North Africa
Procore Technologies, a Carpinteria-based company that provides software to the construction industry, announced an expansion into the Middle East and North Africa on July 6. The effort will be undertaken in partnership with Mubadala Investment Company, a sovereign investor for the government of Abu Dhabi that owns shares in Procore. “The construction sector in the Read More →
Arcutis ends phase 2 trials on potential skin treatment
Shares of Westlake Village-based Arcutis Biotherapeutics dropped by as much as 5% during the trading day July 1, after the biotech company terminated phase 2 trials for a potential treatment. Arcutis, a biotech company focused on creating dermatology treatments, has announced July that it had terminated phase 2a and 2b trials for evaluating ARQ-252, a Read More →
